Invesaro

Stocks Comparison

Agilent Technologies vs 10x Genomics: revenue, profit, margins and growth compared

Agilent Technologies brought in $6.9B of revenue in fiscal 2025, 10x Genomics $642.8M in fiscal 2025. Revenue changed by +6.7% at Agilent Technologies and +5.2% at 10x Genomics on the year before, so Agilent Technologies grew faster. Agilent Technologies kept 18.8% of its revenue as net profit, 10x Genomics -6.8%. Free cash flow was $1.2B at Agilent Technologies and $130.1M at 10x Genomics.

Side by side, latest fiscal year

ATXG
Fiscal year endedFY2025 (October 31, 2025)FY2025 (December 31, 2025)
Revenue$6.9B$642.8M
Revenue growth+6.7%+5.2%
Net income$1.3B-$43.5M
Net margin18.8%-6.8%
Free cash flow$1.2B$130.1M
Free cash flow margin16.6%20.2%
Earnings per share (diluted)$4.57-$0.35
Cash$1.8B$474M
Debt$3.1Bn/a
Price to earnings37.8n/a
Market value$48.8B$11.2B
Dividend yield0.57%n/a
Rank by revenue in sector#97 of 451 · Industrials#299 of 451 · Industrials

Over the years

Revenue
A FY2018: $4.9BA FY2019: $5.2BA FY2020: $5.3BA FY2021: $6.3BA FY2022: $6.8BA FY2023: $6.8BA FY2024: $6.5BA FY2025: $6.9BTXG FY2019: $146.3MTXG FY2019: $245.9MTXG FY2020: $298.8MTXG FY2021: $490.5MTXG FY2022: $516.4MTXG FY2023: $618.7MTXG FY2024: $610.8MTXG FY2025: $642.8MFY18FY19FY20FY21FY22FY23FY24FY25
A $6.9BTXG $642.8M
Net income
A FY2018: $316MA FY2019: $1.1BA FY2020: $719MA FY2021: $1.2BA FY2022: $1.3BA FY2023: $1.2BA FY2024: $1.3BA FY2025: $1.3BTXG FY2019: -$112.5MTXG FY2019: -$31.3MTXG FY2020: -$542.7MTXG FY2021: -$58.2MTXG FY2022: -$166MTXG FY2023: -$255.1MTXG FY2024: -$182.6MTXG FY2025: -$43.5MFY18FY19FY20FY21FY22FY23FY24FY25
A $1.3BTXG -$43.5M
Net margin
A FY2018: 6.4%A FY2019: 20.7%A FY2020: 13.5%A FY2021: 19.1%A FY2022: 18.3%A FY2023: 18.1%A FY2024: 19.8%A FY2025: 18.8%TXG FY2019: -76.9%TXG FY2019: -12.7%TXG FY2020: -181.6%TXG FY2021: -11.9%TXG FY2022: -32.1%TXG FY2023: -41.2%TXG FY2024: -29.9%TXG FY2025: -6.8%FY18FY19FY20FY21FY22FY23FY24FY25
A 18.8%TXG -6.8%
Revenue growth
A FY2019: +5.1%A FY2020: +3.4%A FY2021: +18.4%A FY2022: +8.4%A FY2023: -0.2%A FY2024: -4.7%A FY2025: +6.7%TXG FY2019: +68.1%TXG FY2020: +21.5%TXG FY2021: +64.1%TXG FY2022: +5.3%TXG FY2023: +19.8%TXG FY2024: -1.3%TXG FY2025: +5.2%FY19FY20FY21FY22FY23FY24FY25
A +6.7%TXG +5.2%
Free cash flow
A FY2018: $910MA FY2019: $866MA FY2020: $802MA FY2021: $1.3BA FY2022: $1BA FY2023: $1.5BA FY2024: $1.4BA FY2025: $1.2BTXG FY2019: -$82.7MTXG FY2019: -$8.1MTXG FY2020: -$254.6MTXG FY2021: -$122.7MTXG FY2022: -$165.3MTXG FY2023: -$63.8MTXG FY2024: -$5.7MTXG FY2025: $130.1MFY18FY19FY20FY21FY22FY23FY24FY25
A $1.2BTXG $130.1M

Fiscal years as each company reports them; the two may end in different months.

Questions about Agilent Technologies and 10x Genomics

Which is bigger by revenue, Agilent Technologies or 10x Genomics?

Agilent Technologies is bigger by revenue: $6.9B in fiscal 2025, against $642.8M for 10x Genomics in fiscal 2025.

Which keeps more of its revenue as profit, Agilent Technologies or 10x Genomics?

Agilent Technologies had a net margin of 18.8% in fiscal 2025; 10x Genomics had -6.8% in fiscal 2025.

Which grew revenue faster, Agilent Technologies or 10x Genomics?

In their latest fiscal years revenue changed by +6.7% at Agilent Technologies and +5.2% at 10x Genomics.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies